A Study to Evaluate the Effect of XY0206 on the QTc Interval in Chinese Healthy Participants

NCT07162116 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

45

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemia With FLT3/ITD Mutation

Interventions

DRUG: XY0206
DRUG: Moxifloxacin (400 mg)
OTHER: XY0206 Placebo

Sponsor

Shijiazhuang Yiling Pharmaceutical Co. Ltd